169 related articles for article (PubMed ID: 9443628)
1. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.
Jacquet P; Averbach A; Stuart OA; Chang D; Sugarbaker PH
Cancer Chemother Pharmacol; 1998; 41(2):147-54. PubMed ID: 9443628
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
3. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration.
Jacquet P; Stuart OA; Chang D; Sugarbaker PH
Anticancer Drugs; 1996 Jul; 7(5):596-603. PubMed ID: 8862729
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intraperitoneal gemcitabine in a rat model.
Pestieau SR; Stuart OA; Chang D; Jacquet P; Sugarbaker PH
Tumori; 1998; 84(6):706-11. PubMed ID: 10080682
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
[TBL] [Abstract][Full Text] [Related]
6. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
Jacquet P; Averbach A; Stephens AD; Stuart OA; Chang D; Sugarbaker PH
Oncology; 1998; 55(2):130-8. PubMed ID: 9499187
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.
Behnia K; Boroujerdi M
J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085
[TBL] [Abstract][Full Text] [Related]
8. Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis.
Sørensen O; Andersen AM; Kristian A; Giercksky KE; Flatmark K
J Surg Oncol; 2014 May; 109(6):521-6. PubMed ID: 24347444
[TBL] [Abstract][Full Text] [Related]
9. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
11. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
12. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
13. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735
[TBL] [Abstract][Full Text] [Related]
14. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors.
Willerding L; Limmer S; Hossann M; Zengerle A; Wachholz K; Ten Hagen TL; Koning GA; Sroka R; Lindner LH; Peller M
J Control Release; 2016 Jan; 222():47-55. PubMed ID: 26658073
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
Darvari R; Boroujerdi M
Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
[TBL] [Abstract][Full Text] [Related]
16. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer.
Nicoletto MO; Padrini R; Galeotti F; Ferrazzi E; Cartei G; Riddi F; Palumbo M; De Paoli M; Corsini A
Cancer Chemother Pharmacol; 2000; 45(6):457-62. PubMed ID: 10854132
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Sugarbaker PH; Stuart OA; Carmignani CP
Cancer Chemother Pharmacol; 2006 May; 57(5):703-8. PubMed ID: 16096789
[TBL] [Abstract][Full Text] [Related]
19. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
